ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1962

Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis

Nouran Eshak1, Kristina Yancey2, Felipe Martinez3, Lester Mertz1, carolyn mead harvey4, Kenneth Warrington5, Matthew Koster5 and Megan Sullivan1, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic Arizona, Phoenix, AZ, 3Mayo Clinic Arizona, Phoenix, 4Mayo Clinic Florida, Jacksonville, FL, 5Mayo Clinic, Rochester, MN

Meeting: ACR Convergence 2024

Keywords: Imaging, Polyarteritis nodosa, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Medium vessel vasculitis (MVV), including polyarteritis nodosa (PAN), presents significant diagnostic challenges with patients frequently exhibiting non-specific systemic manifestations. While 18F-fluorodeoxyglucose PET/CT (PET/CT) is widely used for large vessel vasculitis, its application in MVV is unclear. A previous case series of 10 patients by Fagart et al. has shown that FDG-PET/CT can reveal characteristic abnormalities such as increased tracer uptake in muscle compartments and medium sized vessels. This study evaluates the diagnostic efficacy of PET CT in a cohort of patients with medium vessel vasculitis.

Methods: This retrospective study utilized data from Mayo Clinic’s records. We reviewed 369 charts and identified 45 patients diagnosed with MVV who underwent PET/CT scans for disease evaluation. Patients were categorized into four groups: PAN meeting classification criteria (n=16, 35.6%), clinician-diagnosed PAN (n=15, 33.3%), medium vessel vasculitis not diagnosed as PAN (n=11, 24.4%), and cutaneous PAN (n=3, 6.7%). Descriptive statistics are reported by group, and differences were tested using Kruskal-Wallis and Fisher’s exact tests.  

All PET/CT scans were performed without intravenous contrast. They were considered positive if the vessel wall tracer activity was higher than the blood pool activity regardless of CT findings. Active myositis was defined as increased FDG accumulation higher than normal muscle background activity. 

Results: Of the 45 patients, 27 (60%) were male and 39 (88.6%) were white, with a mean age at diagnosis of 55.8 years. Clinical manifestations included constitutional symptoms in 29 (64.4%), neurologic involvement in 19 (42.2%), and muscle involvement in 21 (46.7%). Biopsies were done in 30 patients and showed evidence of vasculitis in 20 (66.7%). Excluding those with cutaneous PAN, PET/CT scans were positive, i.e., showed evidence of FDG uptake in vessels, in 13 (31%) patients and negative in 27 (64.2%), 2 (4.8%) were non-specific (defined as muscle uptake only).

Common PET/CT findings included uptake in lower extremity vessels (10), muscles (7), and iliac arteries (5). The most common pattern of muscle uptake was linear (6/7). Location of uptake did not differ significantly between disease groups. Glucocorticoid use prior to PET/CT was common and reported in 19 (45.2%). Of those without prior glucocorticoid use 11/23 (47.8%) were positive versus 2/19 (10.5%) with prior use. Prior glucocorticoid use was inversely associated with a positive PET/CT (p=0.017). 

Conclusion: PET/CT scans can show characteristic findings in MVV, with predominant involvement of lower extremity vessels and linear muscle uptake. However, there is limited sensitivity for diagnosing MVV and this can be further influenced by glucocorticoid use, highlighting the need for careful consideration of pre-scan treatment regimens. These findings suggest that PET/CT should be used with other diagnostic modalities for a comprehensive evaluation. 

References:
1Fagart, A. et al. “Fluorodeoxyglucose positron emission tomography–computed tomography findings in a first series of 10 patients with polyarteritis nodosa.” Rheumatology 61.4 (2022): 1663-1668.

Supporting image 1

18-FDG PET/CT scan findings in patients with medium vessel vasculitis

Supporting image 2

Table 1: Clinical Characteristics, Labs, Biopsy and Imaging in patients with Medium Vessel Vasculitis

Supporting image 3

Table 2: 18 FDG-PET/CT Scan Findings among non-cutaneous PAN.


Disclosures: N. Eshak: None; K. Yancey: None; F. Martinez: None; L. Mertz: None; c. mead harvey: None; K. Warrington: Amgen, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 5, sanofi, 2; M. Koster: Amgen, 1; M. Sullivan: None.

To cite this abstract in AMA style:

Eshak N, Yancey K, Martinez F, Mertz L, mead harvey c, Warrington K, Koster M, Sullivan M. Utility of 18 FDG-PET/CT Scans in the Diagnosis of Polyarteritis Nodosa and Other Medium Vessel Vasculitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/utility-of-18-fdg-pet-ct-scans-in-the-diagnosis-of-polyarteritis-nodosa-and-other-medium-vessel-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-18-fdg-pet-ct-scans-in-the-diagnosis-of-polyarteritis-nodosa-and-other-medium-vessel-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology